

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司** \*

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, 31 August 2022 for the purposes of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 and its publication, and considering the payment of an interim dividend, if any.

By order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 19 August 2022

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* For identification purposes only